Transarterial chemoembolization treatment: Association between multiple treatments, cumulative expenditures, and survival

Value in Health

Volumn 16, Issue 5, 2013, Pages 760-768

  Breunig, Ian M ^a   Shaya, Fadia T ^a   Hanna, Nader ^b   Seal, Brian ^c   Chirikov, Viktor V ^a   Daniel Mullins, C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

cost effectiveness; hepatocellular carcinoma; SEER Medicare; survival transarterial chemoembolization

Indexed keywords

AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; CHEMOEMBOLIZATION; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; RISK FACTOR;

COST-EFFECTIVENESS; HEPATOCELLULAR CARCINOMA; SEER-MEDICARE; SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTINENTAL POPULATION GROUPS; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LIVER NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; UNITED STATES;

EID: 84881661853     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.03.1630     Document Type: Article

References (27)

1. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. S.F. Altekruse, K.A. McGlynn, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
3. H.B. El-Serag, J.A. Davila, N.J. Petersen, and K.A. McGlynn The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 2003 817 823
4. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 2012 1264 1273 e1
5. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
6. K.M. Kim, J.H. Kim, and I.S. Park Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion J Gastroenterol Hepatol 24 2009 806 814
7. R. Lencioni Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy Crit Rev Oncol Hematol 83 2012 216 224
8. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
9. B. Rampone, B. Schiavone, and A. Martino Current management strategy of hepatocellular carcinoma World J Gastroenterol 15 2009 3210
10. Z.W. Peng, Y.J. Zhang, and H.H. Liang Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial Radiology 262 2012 689 700
11. H. Kinugasa, K. Nouso, and Y. Takeuchi Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma J Gastroenterol 47 2011 421 426
12. L. Marelli, R. Stigliano, and C. Triantos Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25
13. M. Mendizabal, and K.R. Reddy Current management of hepatocellular carcinoma Med Clin North Am 93 2009 885 900 viii
14. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
15. H.J. Jaeger, U.M. Mehring, and F. Castaneda Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma Cardiovasc Intervent Radiol 19 1996 388 396
16. K. Lang, N. Danchenko, and K. Gondek The burden of illness associated with hepatocellular carcinoma in the United States J Hepatol 50 2009 89 99
17. J.L. Warren, C.N. Klabunde, and D. Schrag Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 2002 3 18
18. R. Golfieri, A. Cappelli, and A. Cucchetti Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5cm) hepatocellular carcinoma Hepatology 53 2011 1580 1589
19. M.H. Ho, C.Y. Yu, and K.P. Chung Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma Ann Surg Oncol 18 2011 3632 3639
20. M. Schemper, S. Wakounig, and G. Heinze The estimation of average hazard ratios by weighted Cox regression Stat Med 28 2009 2473 2489
21. ® macro for weighted parameter estimation for Cox's model. Available from: http://www.meduniwien.ac.at/cemsiis/ en/kb/science-research/software/statistical-software/. [Accessed February 16, 2012].
22. H. Bang, and A.A. Tsiatis Estimating medical costs with censored data Biometrika 87 2 2000 329 343
23. D.Y. Lin Linear regression analysis of censored medical costs Biostatistics 1 1 2000 35 47
24. R.I. Griffiths, M.L. Gleeson, M.D. Danaes, and A. O'Hagan Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare Value Health 15 2012 656 663
25. A. Basu, and W.G. Manning Estimating lifetime or episode-of-illness costs under censoring Health Econ 19 9 2010 1010 1028
26. R.I. Griffiths, R.L. Barron, and M.L. Gleeson Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer Pharmacoeconomics 30 2 2012 103 118
27. G.W. Imbens Nonparametric estimation of average treatment effects under exogeneity: a review Rev Econ Stat 86 1 2004 4 29